137 related articles for article (PubMed ID: 21042320)
21. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
22. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
23. Detection of minimal residual disease by PCR in childhood T-cell acute lymphoblastic leukemia with TAL1 gene rearrangement: a preliminary report.
Kikuchi A; Hanada R; Yamamoto K; Hayashi Y
Med Pediatr Oncol; 1999 Feb; 32(2):148. PubMed ID: 9950206
[No Abstract] [Full Text] [Related]
24. MLL fusion genes in the 11q23 acute leukemias.
Downing JR; Look AT
Cancer Treat Res; 1996; 84():73-92. PubMed ID: 8724626
[No Abstract] [Full Text] [Related]
25. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
26. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
[TBL] [Abstract][Full Text] [Related]
27. Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias.
Alessandri AJ; Knezevich SR; Mathers JA; Schultz KR; Sorensen PH
Med Pediatr Oncol; 2001 Oct; 37(4):415-6. PubMed ID: 11568911
[No Abstract] [Full Text] [Related]
28. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
29. Amplification of AML1 in childhood acute lymphoblastic leukemias.
Dal Cin P; Atkins L; Ford C; Ariyanayagam S; Armstrong SA; George R; Cleary A; Morton CC
Genes Chromosomes Cancer; 2001 Apr; 30(4):407-9. PubMed ID: 11241794
[TBL] [Abstract][Full Text] [Related]
30. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
31. FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse.
Wellmann S; Moderegger E; Zelmer A; Bettkober M; von Stackelberg A; Henze G; Seeger K
Leukemia; 2005 Mar; 19(3):467-8. PubMed ID: 15674414
[No Abstract] [Full Text] [Related]
32. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R; Miething C; Thiede C; Peschel C; Duyster J
Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
34. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia.
Konstandin N; Bultmann S; Szwagierczak A; Dufour A; Ksienzyk B; Schneider F; Herold T; Mulaw M; Kakadia PM; Schneider S; Spiekermann K; Leonhardt H; Bohlander SK
Leukemia; 2011 Oct; 25(10):1649-52. PubMed ID: 21625234
[No Abstract] [Full Text] [Related]
35. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
[TBL] [Abstract][Full Text] [Related]
36. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
[TBL] [Abstract][Full Text] [Related]
37. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.
Sulong S; Case M; Minto L; Wilkins B; Hall A; Irving J
Br J Haematol; 2005 Sep; 130(6):964-5. PubMed ID: 16156866
[No Abstract] [Full Text] [Related]
38. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
39. [Cancer and fusion gene].
Nakata M; Ohki M
Tanpakushitsu Kakusan Koso; 1997 Sep; 42(12):1978-90. PubMed ID: 9301327
[No Abstract] [Full Text] [Related]
40. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
